Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of eighty three dolars, and that is approximately 9.11 % above the existing share price of $76.07.
Cherny expects CVS Health Corp to post earnings per share (EPS) of $0.93 for the earliest quarter of 2021.
The analysts priced targets range from a high of hundred one dolars to a low of sixty one dolars.
In its newest earnings report, released on 09/30/2020, the company found a quarterly revenue of $67.06 billion and a net gain of $3.25 billion. The company’s market cap is $99.57 billion.
According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0-5 stars ranking scale, with an average return of 11.5 % along with a 60.53 % success rate.
CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, retail or Long Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment offers pharmacy benefit management solutions. The Long or retail Term Care segment includes selling of prescribed drugs as well as assortment of general merchandise.
The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioural health, healthcare relief capabilities. The Corporate segment involves in providing management and administrative services. The company was created by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.